Deva Holding posted TRY 607.7 million profit. Deva Holding stock sat 30.15 percent below high
Published on 10/19/2026 at 02:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSHalf-year results and market context
- Deva Holding reported TRY 607.7 million net profit for the six months ended June 30, 2026.
- Quarterly sales reached TRY 6.4 billion and quarterly EBITDA was TRY 1.5 billion in the 2026 second quarter.
- Deva Holding stock was last at TRY 76.35 on Borsa Istanbul on October 16, 2026.
- The company operates across 15 therapeutic areas and serves more than 80 countries.
Deva Holding (TRADEVAW91E2) reported TRY 607.7 million net profit for the six months ended June 30, 2026, in results listed by MarketScreener on August 14, 2026, while the financial table was detailed by Yatirimci.AI. The stock was last at TRY 76.35 on Borsa Istanbul on October 16, 2026.
What did the half-year show?
Quarterly sales reached TRY 6.4 billion in the second quarter of 2026, up from TRY 5.9 billion in the first quarter of 2026. Quarterly EBITDA rose to TRY 1.5 billion from TRY 754.6 million over the same period, while quarterly net profit moved from a loss of TRY 90.9 million to a profit of TRY 607.7 million.
The annualized figures present a more cautious backdrop. Annualized sales stood at TRY 20.2 billion in the period ending June 30, 2026, but annualized net profit remained negative at TRY 1.1 billion. That contrast makes the latest quarterly profit a recovery signal, while the twelve-month measure still reflects earlier weakness.
Three reporting milestones
On March 6, 2026, Deva Holding published fiscal 2025 results, with quarterly sales of TRY 5.5 billion and quarterly EBITDA of TRY 341.1 million in the December 2025 period. On May 8, 2026, it published first-quarter results, when sales were TRY 5.9 billion and EBITDA was TRY 754.6 million. On August 14, 2026, the company reported second-quarter and six-month results, including TRY 6.4 billion in quarterly sales and TRY 607.7 million in quarterly net profit, according to MarketScreener and Yatirimci.AI.
How broad is the operating base?
DEVA Holding develops and manufactures human pharmaceuticals, active pharmaceutical ingredients and veterinary products. Its portfolio covers 15 therapeutic areas, and its international network reaches more than 80 countries. The company also operates US FDA and EU GMP-approved manufacturing facilities.
Stock stays below its yearly high
Deva Holding stock was 30.15 percent below its 52-week high of TRY 109.30 on October 16, 2026, when the last price was TRY 76.35. The same source placed the 52-week low at TRY 57.50 and market capitalization at TRY 15.3 billion. The valuation picture therefore combines a strong latest quarter with a still-negative annualized profit figure.
The last available price was TRY 76.35 on Borsa Istanbul on October 16, 2026.
Deva Holding stock facts
- Company: Deva Holding A.?.
- ISIN: TRADEVAW91E2
- Ticker: DEVA
- Primary exchange: Borsa Istanbul
- Price on Borsa Istanbul (as of October 16, 2026): TRY 76.35
- Market capitalization: TRY 15.3 billion (as of October 16, 2026)
- 52-week range: TRY 57.50-109.30 (as of October 16, 2026)
- Sector / Industry: Chemicals, Petroleum, Rubber and Plastics / Pharmaceuticals
Market context: Market report BIST 100.
